Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Revenue recognized from beginning-of-year deferred by Year
Revenue recognized from beginning-of-year deferred revenue balance ($M) ($M)
Moderna Revenue recognized from beginning-of-year deferred: $320M in FY2025, up 21.2% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Revenue recognized from beginning-of-year deferred revenue balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 320 | +21.2% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 264 | -51.8% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 548 | -78.3% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 2,526 | -78.4% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 11,696 | +191.7% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 4,010 | – | Form 10-K (filed 2021-02-26) ↗ |
Breakdown
What makes up revenue recognized from beginning-of-year deferred
- Recognized from beginning deferred revenue — Product sales ($M)108 · FY2025
- Recognized from beginning deferred revenue — Other revenue ($M)212 · FY2025
- Recognized from beginning deferred revenue — Collaborations (legacy) ($M)12 · FY2024
- Recognized from beginning deferred revenue — Grants (legacy) ($M)7 · FY2024
Cite this data
StockData. (2026). Moderna Revenue recognized from beginning-of-year deferred ($M), annual FY2020–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-recognized-beg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.